Leg weakness in a 66-year-old woman: A common presentation of an uncommon disease

Cleveland Clinic Journal of Medicine

Volumn 74, Issue 1, 2007, Pages 23-34

  Stojic, Andrey S ^a   Mekhail, Tarek ^a   Tsao, Bryan E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; CARBOPLATIN; ETOPOSIDE; PREDNISONE; PYRIDOSTIGMINE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD PRESSURE MEASUREMENT; CACHEXIA; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DIZZINESS; DRUG WITHDRAWAL; EATON LAMBERT SYNDROME; ELECTROMYOGRAPHY; FEMALE; GAIT DISORDER; HEART RATE; HUMAN; LAMINECTOMY; LIMB WEAKNESS; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MUSCLE STRENGTH; MYOSITIS; NERVE STIMULATION; NEUROMUSCULAR DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC NEUROPATHY; PARESTHESIA; PATIENT COMPLIANCE; PLASMAPHERESIS; POLYNEUROPATHY; PROPRIOCEPTION; RADICULOPATHY; REVIEW; SENSORIMOTOR NEUROPATHY; SITTING; SMOKING; SPINAL CORD METASTASIS; SPONDYLOSIS; STANDING; TENDON REFLEX; VIBRATION; XEROSTOMIA;

EID: 33846315490     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.74.1.23     Document Type: Review

References (26)

1. Brazis PW, Masdeu JC, Biler J. Localization in Clinical Neurology, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:101-127.
2. Pioro EP. Motor neuron disorders. In: Levin KH, Lüders HO, editors. Comprehensive Clinical Neurophysiology. Philadelphia: W.B. Saunders, 2000:235-250.
3. Bosch EB, Smith BE. Disorders of peripheral nerves. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, editors. Neurology in Clinical Practice, 4th ed. Philadelphia: Butterworth-Heinemann, 2004:2299-2402.
4. Sanders DB, Howard JF Jr. Disorders of neuromuscular transmission. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, editors. Neurology in Clinical Practice, 4th ed. Philadelphia: Butterworth-Heinemann, 2004:2441-2462.
5. Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002; 73:766-768.
6. Amato AA, Brooke MH. Disorders of skeletal muscle. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, editors. Neurology in Clinical Practice, 4th ed. Philadelphia: Butterworth-Heinemann, 2004:2463-2510.
7. Chiou-Tan F, Tim RW, Gilchrist JM, et al. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. AAEM Quality Assurance Committee, American Association of Electrodiagnostic Medicine. Muscle Nerve 2001; 24:1239-1247.
8. Levin KH. Disorders of neuromuscular junction transmission. In: Levin KH, Lüders HO, editors. Comprehensive Clinical Neurophysiology. Philadelphia: W.B. Saunders, 2000:251-267.
9. van Zwieten PA. Adrenergic and cholinergic receptors. In: Mathias CJ, Bannister R, editors. Autonomic Failure: a Textbook of Clinical Disorders of the Autonomic Nervous System. New York: Oxford University Press, 1999:56-62.
10. Sandroni P, Vernino S, Klein CM, et al. Idiopathic autonomic neuropathy: comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol 2004, 61:44-48.
11. Lang B, Vincent A. Autoantibodies to ion channels at the neuromuscular junction. Autoimmun Rev 2003; 2:94-100.
12. Kleopa KA, Teener JW, Scherer SS, Galetta SL, Bird SJ. Chronic multiple paraneoplastic syndromes. Muscle Nerve 2000; 23:1767-1772.
13. Leonovicz BM, Gordon EA, Wass CT. Paraneoplastic syndromes associated with lung cancer: a unique case of concomitant subacute cerebellar degeneration and Lambert-Eaton myasthenic syndrome. Anesth Analg 2001; 93:1557-1559.
14. Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin Neurol 2003; 2:191-198.
15. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989; 321:1567-1571.
16. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000; 54:603-607.
17. Oh SJ, Kim DS, Head TC, Claussen GC. Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1997; 20:1146-1152.
18. Lundh H, Nilsson O, Rosen I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984; 34:1324-1330.
19. Streib EW, Rothner AD. Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone. Ann Neurol 1981; 10:448-453.
20. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases. JAMA 2004; 291:2367-2375.
21. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996; 47:678-683.
22. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984; 34:480-485.
23. Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2005; 18:CD003279.
24. O'Neill JH, Murray MF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. Brain 1988; 111:577-596.
25. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung cancer. Neurology 1990; 40:1552-1556.
26. Maddison P, Lang B, Mill K, Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 2001; 70:212-217.